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Summary.-Fifteen patients with acute myelogenous leukaemia were studied to
determine if their remission blood leucocytes could be stimulated into taking up
[3H] thymidine after in vitro culture with their own cryo-preserved irradiated AML
leukaemia cells. In 6/15 patients it was possible to show autologous recognition,
and equal recognition of their stored leukaemia cells, even when they had previously
been maintained in in vitro proliferative cultures in liquid suspension and under-
going myeloid maturation for one week. After in vitro proliferative culture, 4 popu-
lations of leukaemia cells produced material in the supernatant media between 3 and
7 days capable of inducing [3H] thymidine uptake in autologous (2 pts, 5 super-
natants) and allogeneic (2 pts, 2 supernatants) AML remission lymphocytes, but not
in normal donor lymphocytes. The relevance of these observations to tumour-
associated AML antigen is discussed.
ANTIBODIES raised in foreign species
have revealed on the plasma membrane of
cells derived from leukaemic patients a
variety of antigens which are absent from
normal adult leucocytes (Mohanakumar,
Metzgar and Miller, 1974, 1975; Mann,
Halterman and Leventhal, 1974; Baker
et al., 1976). These investigations do not,
however, show whether these new antigens
will also be recognized by patients or
whether they are, like many foetal, cell-
cycle specific or differentiation antigens,
macromolecules which reappear on malig-
nant cells but to which the autologous host
does not respond. The most compelling
data for the presence of a " neo-antigen "
on the surface of AML cells relies on the
stimulation in mixed leucocyte reactions
(MLR) of DNA synthesis of the blood
leucocytes of patients in remission by
autologous leukaemia cells which were
collected at presentation and then stored
frozen (Viza et al., 1969; Fridman and
Kourilsky, 1969; Powles et al., 1971;
Powles, 1974; Fefer, Mickelson and
Thomas, 1976). The observation that
these neo-antigens were not present on
remission marrow and that, following
immunization with irradiated leukaemia
cells, the lymphocytes from AML patients
in remission responded more strongly to
autologous leukaemia cells (Powles et al.,
1971) was our principal reason for initiat-
ing a controlled clinical trial (Powles et al.,
1973, 1977) to determine the effect of
immunizing AML patients in remission
with irradiated AML cells.
There are, however, atleasttworeasons
why a positive MLR induced by auto-
logous leukaemia cells may not be attri-
butable to a specific leukaemia antigen.
First, recent studies (unpublished)
have shown that the leukaemia cells from
patients with AML frequently have recep-
tors in their membranes for the distorted
Fc component of normal immunoglobulin
and that, therefore, AML cells removed
from the blood and frozen may contain
bound immune complexes. This raises
the possibility that the stimulation of
autologous lymphocytes induced by the
stored leukaemia cells may not be initiated
by neo-antigen, but may be a response to
bound immune complexes which areP. COCKS, R. POWLES, B. CHAPUIS AND P. ALEXANDER
totally non-specific to the tumour. Lym-
phocytes from patients with autoimmune
diseases who are producing rheumatoid
factor are stimulated by immune com-
plexes, presumably because they recognize
the Fc part of the complex as foreign
(Weisbart, Bluestone and Goldberg, 1975).
However, we now report experiments in
which AML cells grown in vitro, and
devoid of surface-bound immunoglobulin,
stimulate autologous remission lympho-
cytes as effectively as non-cultured AML
cells.
Second, there is the possibility that the
observed stimulation of DNA synthesis in
the MLR is not immunological, but is
caused by a mitogenic factor released by
the leukaemic blasts which is similar to the
general mitogenic factors encountered as a
by-product of ordinary MLR reactions
(Kasakura, 1970). If such a non-specific
factor were responsible, the supernatant
from cultures consisting only ofAML cells
should induce DNA synthesis in lympho-
cytes from suitable donors. However,
stimulation obtained in this way would
need to be distinguished from that obtain-
ed by the presence of shed soluble leu-
kaemia-specific antigenwhich could stimu-
late in vitro lymphocytes from donors
previously sensitized to this antigen, in a
manner analogous to the stimulation
induced in the lymphocytes from tuber-
culin-sensitive donors by PPD.
METHODS
Preparation of the lymphocytes.-20 ml of
peripheral blood was taken by venepuncture
from remission AML patients and normal
donors and defibrinated by shaking with
glass beads. The defibrinated blood was
mixed with 6 ml of 1% methyl cellulose
(DOW) and 200 mg offinely divided carbonyl
ironfor30 minat370C (CoulsonandChalmers,
1967), and the red cells and polymorphs were
allowed to settle at 370C. The supematant
was removed and centrifuged at 2000 rev/
min for 5 min. The serum and remaining
methyl cellulose were removed from the
normal donor suspension, and used as a
source of serum. The cell pellet was resus-
pended in 2 ml of TC199 (Wellcome) contain-
ing penicillin and streptomycin and 12.5%
normal serum. The cells were then counted,
and resuspended in the above media to give a
final concentration of 2 x 106 cells/ml.
Preparation ofthe AML cells.-Leukaemia
cells were collected from the patients prior to
remission, using an NCI/IBM Cell Separator
(Powles et al., 1974) and then stored in
dimethylsulphoxide (DMSO) at - 179°C in
2-ml glass ampoules (Chapuis et al., 1977).
Ampoules ofthe required blasts were thawed
rapidly in a 37°C waterbath and diluted very
slowly with 20 ml of medium RPMI 1640
(Gibco/Biocult), centrifuged at 1000 rev/min
for 5 min and resuspended in 10 ml of
medium. The cell suspension was layered on
to anequal volume oflymphoprep (Nyegaard)
and centrifuged at 4000 rev/min for 15 min.
The resulting buffy layer was removed and
washed twice in medium TC199 plus penicillin
and streptomycin. The cell pellet was resus-
pended in 10 ml of culture medium 199 plus
12.5% normal serum. The cells were count-
ed, using trypan blue exclusion, and resus-
pended at a concentration of 2 x 106 viable
cells/ml. To test leukaemia cells in the MLR
after proliferation in vitro, 107 cells in 3 ml of
culture medium were aliquoted into 35-mm
tissue culture dishes (Falcon) and placed in a
5% CO2 incubator (Natco) for one week, as
described in a separate paper (Chapuis et at.,
1977) and then counted and resuspended at
2 x 106 viable cells/ml.
Mixed leucocyte reaction assayed by incor-
poration of [3H]thyrnidine.-Responding lym-
phocyte suspensions were plated in microtest
tissue culture plates (Falcon 3040) in a
volume of0-1 ml per well at a concentration of
2 x 106/ml of TC199 (containing 12.5%
normal donor serum). An equal volume and
concentration of stimulating normal donor
lymphocytes or leukaemia cells (for positive
MCRs) were added to the responding lympho-
cytes afterexposureto2000 radof60Coy-rays.
The total number of cells per well was
4 x 105, and each individual part of the
experiments was done in triplicate. Plates
were incubated in 5% CO2 at 37°C for 6 days
without disturbing the cultures. In our
laboratory, the above conditions are optimum
for MLRs involving normal allogeneic peri-
pheral blast leucocytes.
After 6 days of culture 0-1 juCi of [3H]-
thymidine (10 ,ul) (sp. act. > 5 Ci/mM, Amer-
sham) was added to each well, using a 1-ml
Hamilton syringe. The plates were incu-
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bated for a further 18 h and then the cells
harvested on to glass-fibre filter papers, using
a multiple harvesting device (Mash Ltd).
The discs were placed in 5 ml of a premixed
scintillant (Econofluor, NewEnglandNuclear)
and counted with a Packard Beta Counter.
The results are presented as ct/min. Each
complete experiment involved the following
controls:
(I) Capacity ofirradiated AML cells (both
before and after culture) to stimulate allo-
geneic lymphocytes fromn normal donors.
(II) Capacity of the lymphocytes from
AML patients in remission to be stimulated
by irradiated allogeneic lymphocytes from
normal donors.
(III) " Background" incorporation of
[3H]thymidine by the individual cell popula-
tion (both responding lymphocytes and
irradiated stimulating lymphocytes or leu-
kaemia cells) after unmixed culture.
Stimulation by culture supernatants.-
Cryopreserved AML cells were grown in pro-
liferative culture as above with medium
TC199 with 12.5% normal serum which was
replaced every 2 days. After 6 days the cell
suspension was centrifuged at 450g for 4min
and the supernatant passed through a 2-,um
millipore filter. Remissionlymphocytes from
the same patient were prepared as described
above, and suspended at a concentration of
2 x 106/ml in 0-1 ml of TC199 plus 12.5%
normal serum. To this was added 0-1 ml of
supernatant atvarious dilutionsinTC199, and
the resulting suspensions cultured in 5% CO2
at 37°C for either 3 or 7 days. Stimulation
was determined using [3H]thymidine as
described above. Supernatants were also
tested for their capacity to stimulate remis-
sionlymphocytes from AML patients who had
not provided the leukaemia cells used in the
oulture, and for lymphocytes from normal
donors.
following contact with autologous AML
cells, is that the former should be immuno-
logically " intact ", as judged by their
ability to respond in the standard one-way
mixed-lymphocyte reaction (MLR) using
normal donor lymphocytes as stimulating
cells. Immediately following the inten-
sive chemotherapy used to induce remis-
sion, we have found that AML patients
show a remarkable day-to-day fluctuation
in their one-way MLR, so that one week
their capacity to respond is within the
normal range and the next it can be
depressed, only to return to normal one
week later (Alexander and Powles, 1973).
Such variations are also seen when auto-
logous AML cells are used as stimulants,
and an instance of this is shown in Fig. 1.
Five weeks after the cessation of all
chemotherapy, the lymphocytes of the
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RESULTS
Capacity of AML cells before and after in
vitro culture to induce DNA synthesis of
autologous remission lymphocytes
Lymphocytes from 15 patients in
haematological remission were studied.
An essential prerequisite, to determine the
capacity of remission lymphocytes to be
stimulated to take up [3H]thymidine
Fig. 1-This patient was studied from 5 to 18
weeks after all chemotherapy had stopped,
and remained in full haematological remis-
sion. During this period, weekly immuno-
therapy of irradiated AML cells and BCG
was given. Stimulation ofbloodleucocytes
in culture has been expressed as ct/min of
[3H]TdR uptake. Pt alone; control cult-
ures of unstimulated leucocytes: Pt + NR;
response to normal allogeneic irradiated
leucocytes: Pt + BIR(O); to freshly thawed
autologous irradiated leukaemic cells: and
Pt + BlR (1 wk); to the same leukaemic
cells after one week in proliferative culture.
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patient did not respond either to allo-
geneic lymphocytes or to autologous AML
cells, and there was a high " background "
thymidine incorporation into these lym-
phocytes, probably due to the presence of
immature cells in the blood. By 9 weeks
they still did not respond, but the high
" background " had disappeared. At 16
weeks an excellent stimulation to both
allogeneic lymphocytes and to auto-
logous AML cells was observed, but at 18
weeks they once again failed to respond to
either type of stimulating cell.
Furthermore, to compare the stimula-
tion ofremission lymphocytes by cultured
and non-cultured stored AML cells, it is
obviously necessary that the stored leu-
kaemia cells grow sufficiently well in
culture to provide a population that is
capable of stimulating allogeneic lympho-
cytes from normal donors.
The requirement that the remission
lymphocytes respond to irradiated allo-
geneic lymphocytes from normal controls,
and that irradiated leukaemia cells are
capable of stimulating normal lympho-
cytes, was met in 6/16 patients studied.
Table I shows that in 5 of these 6 the
remission lymphocytes were stimulated by
autologous AML cells, both before and
after culture, to about the same extent.
In the case ofthe 6th patient who respond-
ed to allogeneic lymphocytes and leu-
kaemia cells, no stimulation was observed
with the autologous AML cells, whether
cultured or not. The magnitude of the
reaction to autologous blasts was less than
that to allogeneic blasts and, in 4 of the 5
cases, allogeneic blasts stimulated better
than allogeneic lymphocytes from normal
donors.
Stimulation of remission lymphocytes by
supernatants of AML cultures
The supernatant of all cultures of
actively growing AML cells has always
failed to stimulate lymphocytes from
normal donors, but 2 patients (5 super-
natants) tested in an autologous situation
induced an increase in [3H]thymidine
incorporation comparable to that ofa one-
way MLR with remission lymphocytes
from AML patients (see Table II). Super-
natants from 2 populations ofproliferative
AML cultures could not be tested in the
autologous situation because the donors
TABLE II.-Stimulation ofLymphocytesfromPatients in Remission bySupernatantsfrom
AML Cells after 3 or 7 Days in Culture: Expressed as ct/min after Pulsing with [3H]TdR
Responding lymphocytes from:
Autologous patient Allogeneic patient
in remission in remission Normal donor
A V, VoK A,
Supernatant source
12.5% normal serum for
7 days
12-5% normal serum for
3 days
10% FCS for 3 days
12-5% normal serum for
7 days
12-5% normal serum for
3 days
12-5% normal serum for
3 days
15% FCS for 3 days
Cc
m
(O
(O
(O
(O
(O
Dntrol Control
tedium Supernatant medium
0 7 1-6 NT
*5-1*0) (1*3-1*9)
0 3 2-4 NT
2-0 4) (1-.5-4-1)
0 4 6-5 NT
3-0 5) (6 3-6 8)
0-6 3-7 NT
*4-0-9) (3-0-4-3)
0 7 3-9 NT
*6-0*9) (3.7-4.2)
NT NT 0-4
(0 3-0 6)
NT NT 0 6
(0*4-0*9)
Control
Supernatant medium Supernatant
NT 0-09
(0.05-0.2)
NT 0 09
(0.07-0.2)
NT 0-2
(0*07--0*2)
NT 0 3
(0.2-0.4)
NT 4-2*
(358-4 6)
3-8 0*9
(2.6-4*5) (0.6-1 .1)
11-9 0 3
(9*4-13*7) (0*2-0*4)
0-2
(0 2-0 3)
0-2
(0*2-0 3)
1.0
(0*5-1*9)
0*2
(0 2-0 2)
5.8*
(4-9-6 4)
0 7
(0 6-0 8)
0-6
(O 3-0 * 8)
NT = Not Tested.
* Occasionally, and unexplained, we find that certain laboratory personnel, used as normal donors, often
have high reactivity in their unstimulated lymphocytes. We have only seen this since using the micro
technique and CO2 incubators, but they still do not respond to supernatant factor.
Pt.
L
L
L
B
B
0
p
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failed to go into remission. Both these
supernatants caused stimulation of allo-
geneic AML lymphocytes but not of
normal lymphocytes. The 5 autologously
active supernatants have not yet been
tested against other patients. Super-
natants from 3 populations ofproliferative
leukaemia cell cultures failed to stimulate
autologous lymphocytes, in spite of the
fact that these leukaemia cells stimulated
autologous remission lymphocytes. It
would appear thatthe optimum conditions
for obtaining a stimulating supernatant
still have to be elucidated.
DISCUSSION
The ability to grow AML cells after
theyhave been stored at -179°C in short-
term tissue culture has made it possible to
study AML cells after they have under-
gone 3 or more division cycles, and are free
of all bound immunoglobulin or immune
complexes. These cells stimulate normal
lymphocytes as well as, ifnot better than,
normal allogeneic lymphocytes do and we
have found them (unpub.) to be excellent
targets for antibodies to HL-A antigens, as
revealed by both complement and cell-
dependent lysis. The membrane after
culture therefore normally displays HL-A
antigens. The finding that the cultured
leukaemia cells stimulate autologous re-
mission lymphocytes as well as " stored "
leukaemia cells do directly after recovery
from storage at - 179°C is most readily
explained by the presence on these cells of
a leukaemia-specific membrane com-
ponent which is antigenic in the auto-
logous host. Artefacts, such as immune
complexes or denatured proteins, which
could have caused the " stored " AML
cells to stimulate, appear to be excluded
by the activity of the cultured cells. We
have described elsewhere (Chapuis et al.,
1977) how these proliferative cultures,
even at 7 days, have rapidly increasing
proportions of more mature cells of the
myeloid series rather than frank " blast "
cells. As the degree of autologous stimu-
lation is not diminished after culture, the
" leukaemia " antigen(s) may be carried
on cells that have undergone maturation
in vitro. This may explain why blood
leucocytes from patients without circulat-
ing blasts may induce stimulation in
histocompatible sib lymphocytes (Fefer
et al., 1976). If this is the case, relapse
may not be the reappearance ofleukaemia
cells, but rather the failure of maturation
of an emergent leukaemic clone of cells.
These observations are clearly not com-
patible with the leukaemia antigen being a
macromolecule of foetal origin.
The possibility that the stimulation by
AML cells ofautologous lymphocytes does
not have an immunological basis, but is
caused by a mitogenic factor, cannot be
definitely excluded, but seems improbable
because the cells straight from storage at
- 179°C, and having a low general meta-
bolism, are as effective as cultured cells
whichwould be expected to produce such a
factor more readily. Also, the failure of
culture supernatants to stimulate normal
lymphocytes implies that such a putative
mitogenic factor from AML cells, if it
exists, has properties which differ from the
general (non-immunological) mitogenic
factor ofKasakura (1970) which isreleased
bylymphocytes, asthis cannot be detected
in our culture supernatants.
The finding that the degree of stimula-
tion observed in the autologous situation
is similar to that produced by allogeneic
lymphocytes implies, either that the " leu-
kaemia " antigen is as potent as allo-
geneic MLR antigens, or that the reaction
observed is a secondary stimulation, in
that the AML cells encounter lympho-
cytes that have already been sensitized.
The latter interpretation seems the more
likely: (i) because the patients would be
expected to be sensitized during the course
of active disease and subsequent immuno-
therapy with AML cells; (ii) because, occa-
sionally, remission lymphocytes respond
to autologous AML cells when they do not
respond to allogeneic lymphocytes (e.g.
response of patient 9 weeks after chemo-
therapy, Fig. 1). In this case, it may be
that, following chemotherapy, the popula-
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tion of cells which are capable of giving a
primary immunological response is still
reduced, but that memory lymphocytes
have remained and respond to the auto-
logous AML cells; (iii) because in some
instances soluble material in the culture
supernatants behaves like an antigen and
specifically stimulates lymphocytes from
remission patients. In general, soluble
antigens are incapable of inducing peri-
pheral blood lymphocytes to transform
in vitro, unless the donor has been previ-
ously sensitized in vivo. Cells from some
experimental animal tumours have been
foundtorelease tumour-specific membrane
antigens in a soluble form into the culture
supernatant (Currie and Alexander, 1974)
and specific shedding of tumour antigens
has been postulated (Alexander, 1974) to
subvert the immune defences of the host,
and facilitate tumour spread and dis-
semination in the face of an immuno-
logical response. Animal experiments
provide parallels in which malignant
disease recurs following treatment, in spite
of the presence of sensitized lymphocytes,
and the sad fact that nearly all of the
remission AML patients relapse is not,
therefore, necessarily inconsistent with
the simultaneous presence oflymphocytes
sensitized and capable of responding to
leukaemia-specific membrane antigens in a
secondary manner.
We are indebted to the Leukaemia
Research Fund for financial support for
this project.
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